Fundraising Fox

Lumiradx

London · Founded 2016 · Incorporated in Cayman Islands · 2 known investors

LumiraDx develops rapid point-of-care diagnostic tests run on its microfluidic immunofluorescence platform, including a SARS-CoV-2 antigen test that detects the virus from nasal and nasopharyngeal swab samples in about 12 minutes. The tests are intended for near-patient use by healthcare providers to aid in diagnosing COVID-19 infection.

Digital HealthHealthtechMedical Devices

Founders & leadership

JM
Jerry McAleerNamed on SEC filing
NL
Nigel LindnerNamed on SEC filing
RZ
Ron ZwanzigerNamed on SEC filing
DW
David WaltonNamed on SEC filing
SN
Sumit NagpalNamed on SEC filing
PW
Peter WelchNamed on SEC filing
VA
Veronique AmeyeNamed on SEC filing
DS
David ScottNamed on SEC filing

Investors · 2

Bantam GroupWestwood
North Atlantic CapitalPortland · $3M – $12M

Reported raises · per SEC filings

Form D private placements

$831.6M disclosed across 8 of 9 rounds · 2016–2020

▶$164MraisedDec 2020 · 31 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Dorian LeBlancExecutive Officer
  • Donald BerwickDirector
  • Bruce KeoghDirector
  • Lurene JosephDirector
  • Lu HuangDirector
  • Troyen BrennanDirector
  • Amit ThakkerDirector
  • George NebleDirector
  • Gerald ChanDirector
  • Ron ZwanzigerExecutive Officer, Director
  • David ScottExecutive Officer, Director
  • Jerry McAleerExecutive Officer, Director
  • David WaltonExecutive Officer
  • Nigel LindnerExecutive Officer
  • Veronique AmeyeExecutive Officer
  • Tom QuinlanExecutive Officer
  • Peter ScheuExecutive Officer
Offering amount
$164M
Amount sold
$164M
Sales commissions
$1.2M
Placement agents
U.S. Boston Capital Corporation
First sale
Nov 2020
Incorporated
Other, Cayman Islands, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$150MraisedMay 2020 · 118 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Dorian LeBlancExecutive Officer
  • Tom QuinlanExecutive Officer
  • Lurene JosephDirector
  • Nigel LindnerExecutive Officer
  • Veronique AmeyeExecutive Officer
  • Bruce KeoghDirector
  • Lu HuangDirector
  • Peter ScheuExecutive Officer
  • Peter WelchExecutive Officer
  • Troyen BrennanDirector
  • Suresh VaziraniDirector
  • David WaltonExecutive Officer
  • Jerry McAleerExecutive Officer, Director
  • Donald BerwickDirector
  • David ScottExecutive Officer, Director
  • Ron ZwanzigerExecutive Officer, Director
Offering amount
$150M
Amount sold
$150M
Minimum investment
$1M
Sales commissions
$1.1M
Placement agents
U.S. Boston Capital Corporation
First sale
Mar 2020
Incorporated
Other, Cayman Islands, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$52.5MraisedApr 2020 · 20 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Nigel LindnerExecutive Officer
  • Peter ScheuExecutive Officer
  • Donald BerwickDirector
  • Ron ZwanzigerExecutive Officer, Director
  • Tom QuinlanExecutive Officer
  • Suresh VaziraniDirector
  • Bruce KeoghDirector
  • Lurene JosephDirector
  • Troyen BrennanDirector
  • Veronique AmeyeExecutive Officer
  • Lu HuangDirector
  • Jerry McAleerExecutive Officer, Director
  • David WaltonExecutive Officer
  • David ScottExecutive Officer, Director
  • Dorian LeBlancExecutive Officer
  • Peter WelchExecutive Officer
Offering amount
$74M
Amount sold
$52.5M
Minimum investment
$1M
Sales commissions
$900K
Placement agents
U.S. Boston Capital Corporation
First sale
Mar 2020
Incorporated
Other, Cayman Islands, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$75.2MraisedFeb 2020 · 171 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Nigel LindnerExecutive Officer
  • Peter WelchExecutive Officer
  • Jerry McAleerExecutive Officer, Director
  • David ScottExecutive Officer, Director
  • Ron ZwanzigerExecutive Officer, Director
  • Suresh VaziraniDirector
  • Troyen BrennanDirector
  • Lu HuangDirector
  • Lurene JosephDirector
  • Bruce KeoghDirector
  • Donald BerwickDirector
  • Dorian LeBlancExecutive Officer
  • Peter ScheuExecutive Officer
  • Tom QuinlanExecutive Officer
  • Veronique AmeyeExecutive Officer
  • David WaltonExecutive Officer
Offering amount
$150M
Amount sold
$75.2M
Minimum investment
$75K
Sales commissions
$2.7M
Placement agents
U.S. Boston Capital Corporation
First sale
Oct 2019
Incorporated
Other, Cayman Islands, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$76.7MraisedSep 2019 · 188 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Dorian LeBlancExecutive Officer
  • Donald BerwickDirector
  • Bruce KeoghDirector
  • Lurene JosephDirector
  • Lu HuangDirector
  • Troyen BrennanDirector
  • Suresh VaziraniDirector
  • Ron ZwanzigerExecutive Officer, Director
  • David ScottExecutive Officer, Director
  • Jerry McAleerExecutive Officer, Director
  • David WaltonExecutive Officer
  • Nigel LindnerExecutive Officer
  • Peter WelchExecutive Officer
  • Veronique AmeyeExecutive Officer
  • Tom QuinlanExecutive Officer
  • Peter ScheuExecutive Officer
Offering amount
$76.7M
Amount sold
$76.7M
Sales commissions
$1.5M
Placement agents
U.S. Boston Capital Corporation
First sale
Nov 2017
Incorporated
Other, Cayman Islands, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$270MraisedJan 2019 · 256 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • David WaltonExecutive Officer
  • Nigel LindnerExecutive Officer
  • Jerry McAleerExecutive Officer, Director
  • Ron ZwanzigerExecutive Officer, Director
  • Peter WelchExecutive Officer
  • Troyen BrennanDirector
  • Lu HuangDirector
  • Suresh VaziraniDirector
  • David ScottExecutive Officer, Director
  • Lurene JosephDirector
  • Peter ScheuExecutive Officer
  • Veronique AmeyeExecutive Officer
  • Tom QuinlanExecutive Officer
  • Donald BerwickDirector
  • Dorian LeBlancExecutive Officer
  • Bruce KeoghDirector
Offering amount
$300M
Amount sold
$270M
Sales commissions
$8.6M
Placement agents
U.S. Boston Capital Corporation, Leerink Partners
First sale
Aug 2018
Incorporated
Other, Cayman Islands, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$613.2KraisedDec 2016 · 6 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Veronique AmeyeExecutive Officer
  • Sumit NagpalExecutive Officer
  • Nigel LindnerExecutive Officer
  • Jerry McAleerExecutive Officer, Director
  • Ron ZwanzigerExecutive Officer, Director
  • David WaltonExecutive Officer
  • Suresh VaziraniDirector
  • Troy BrennanDirector
  • Peter WelchExecutive Officer
  • Lurene JosephDirector
  • David ScottExecutive Officer, Director
Offering amount
$613.2K
Amount sold
$613.2K
First sale
Nov 2016
Incorporated
Other, Cayman Islands, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$42.6MraisedOct 2016 · 2 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • David ScottExecutive Officer, Director
  • Sumit NagpalExecutive Officer
  • Jerry McAleerExecutive Officer, Director
  • Veronique AmeyeExecutive Officer
  • Nigel LindnerExecutive Officer
  • Ron ZwanzigerExecutive Officer, Director
  • David WaltonExecutive Officer
  • Peter WelchExecutive Officer
Offering amount
$42.6M
Amount sold
$42.6M
Sales commissions
$2.5M
Placement agents
U.S. Boston Capital Corporation
First sale
Oct 2016
Incorporated
Other, Cayman Islands, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Lumiradx do?
LumiraDx develops rapid point-of-care diagnostic tests run on its microfluidic immunofluorescence platform, including a SARS-CoV-2 antigen test that detects the virus from nasal and nasopharyngeal swab samples in about 12 minutes. The tests are intended for near-patient use by healthcare providers to aid in diagnosing COVID-19 infection.
Who are Lumiradx's investors?
Lumiradx's investors include Bantam Group, North Atlantic Capital.
How much funding has Lumiradx raised?
Lumiradx has disclosed $831.6M raised across 8 of its 9 known rounds.
Where is Lumiradx headquartered?
Lumiradx is headquartered in London.